Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study-Reference-Cited by-同舟云学术

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study

Published:2018-11-08 Issue:3 Volume:9 Page:370-383
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discov

Author:

Daver Naval,Garcia-Manero Guillermo,Basu Sreyashi,Boddu Prajwal C.,Alfayez Mansour,Cortes Jorge E.,Konopleva Marina,Ravandi-Kashani Farhad,Jabbour Elias,Kadia Tapan,Nogueras-Gonzalez Graciela M.,Ning Jing^ORCID,Pemmaraju Naveen,DiNardo Courtney D.,Andreeff Michael^ORCID,Pierce Sherry A.,Gordon Tauna,Kornblau Steven M.,Flores Wilmer,Alhamal Zainab,Bueso-Ramos Carlos,Jorgensen Jeffrey L.,Patel Keyur P.,Blando Jorge,Allison James P.^ORCID,Sharma Padmanee,Kantarjian Hagop

Funder

MD Anderson Cancer Center

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 375 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mesenchymal stromal cells in myeloid malignancies: Immunotherapeutic opportunities;Heliyon;2024-02

2. Immunotherapies of acute myeloid leukemia: Rationale, clinical evidence and perspective;Biomedicine & Pharmacotherapy;2024-02

3. Decoding leukemia at the single-cell level: clonal architecture, classification, microenvironment, and drug resistance;Experimental Hematology & Oncology;2024-01-30

4. A murine model to evaluate immunotherapy effectiveness for human Fanconi anemia-mutated acute myeloid leukemia;PLOS ONE;2024-01-30

5. 5-methylcytosine RNA modification regulators-based patterns and features of immune microenvironment in acute myeloid leukemia;Aging;2024-01-25